Company Performance - McKesson's stock closed at $724.11, down 1.53% from the previous session, which is less than the S&P 500's loss of 0.07% [1] - Over the past month, McKesson's shares have appreciated by 3.83%, outperforming the Medical sector's loss of 1.3% and lagging behind the S&P 500's gain of 3.94% [1] Earnings Estimates - McKesson is expected to report earnings of $8.25 per share on August 6, 2025, reflecting a year-over-year growth of 4.7% [2] - The consensus estimate for revenue is projected at $96.08 billion, indicating a 21.18% increase compared to the same quarter of the previous year [2] Full-Year Projections - The full-year Zacks Consensus Estimates for McKesson are earnings of $37.25 per share and revenue of $405.91 billion, representing year-over-year changes of +12.71% and +13.05%, respectively [3] Analyst Sentiment - Recent changes to analyst estimates for McKesson indicate evolving short-term business trends, with positive revisions suggesting optimism about the business outlook [3][4] Zacks Rank - McKesson currently holds a Zacks Rank of 2 (Buy), with the Zacks Consensus EPS estimate shifting 0.16% upward over the past month [5] Valuation Metrics - McKesson's Forward P/E ratio is 19.74, which is a premium compared to the industry average Forward P/E of 18.21 [6] - The company has a PEG ratio of 1.47, while the Medical - Dental Supplies industry average PEG ratio is 1.67 [6] Industry Context - The Medical - Dental Supplies industry, part of the Medical sector, has a Zacks Industry Rank of 29, placing it in the top 12% of over 250 industries [7]

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is BioCryst Pharmaceuticals (BCRX) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.BioCryst Pharmaceuticals is a member of our Medical group, which includes 987 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best ...

Core Viewpoint - McKesson's stock performance has lagged behind the broader market, with upcoming earnings expected to show growth in both EPS and revenue compared to the previous year [1][2][3]. Financial Performance - McKesson is scheduled to report earnings on August 6, 2025, with a forecasted EPS of $8.33, reflecting a 5.71% increase year-over-year [2]. - Revenue is projected to be $95.77 billion, indicating a 20.79% increase compared to the same quarter of the previous year [2]. - For the entire fiscal year, earnings are estimated at $37.23 per share and revenue at $405.85 billion, representing increases of 12.65% and 13.03% respectively from the prior year [3]. Analyst Estimates - Recent revisions in analyst estimates suggest confidence in McKesson's business performance and profit potential [3]. - The Zacks Consensus EPS estimate has increased by 0.09% over the past month, and McKesson currently holds a Zacks Rank of 2 (Buy) [5]. Valuation Metrics - McKesson is trading at a Forward P/E ratio of 19.55, which is higher than the industry average of 17.95, indicating a premium valuation [6]. - The company has a PEG ratio of 1.45, compared to the industry average PEG ratio of 1.68, suggesting a favorable growth outlook relative to its valuation [7]. Industry Context - The Medical - Dental Supplies industry, which includes McKesson, has a Zacks Industry Rank of 23, placing it in the top 10% of over 250 industries [8].

Investors with an interest in Medical - Dental Supplies stocks have likely encountered both Dentsply International (XRAY) and Merit Medical (MMSI) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock char ...

Group 1: Company Performance - Cardinal Health (CAH) closed at $165.61, with a daily increase of +1.14%, outperforming the S&P 500's gain of 0.8% [1] - Over the past month, CAH shares increased by 6.94%, surpassing the Medical sector's gain of 3.12% and the S&P 500's gain of 5.12% [1] Group 2: Upcoming Financial Results - The upcoming EPS for Cardinal Health is projected at $2.02, indicating a 9.78% increase year-over-year [2] - The Zacks Consensus Estimate for revenue is $60.65 billion, reflecting a 1.31% increase from the previous year [2] Group 3: Full Year Projections - For the full year, earnings are projected at $8.18 per share, representing an increase of +8.63%, while revenue is expected to be $223.07 billion, a decrease of -1.72% from the prior year [3] Group 4: Analyst Estimates and Stock Performance - Changes in analyst estimates for Cardinal Health are important as they reflect short-term business trends and analysts' confidence in performance [4] - The Zacks Rank system, which incorporates estimate changes, indicates Cardinal Health holds a Zacks Rank of 2 (Buy) [6] Group 5: Valuation Metrics - Cardinal Health has a Forward P/E ratio of 20.03, which is higher than the industry average of 17.14 [7] - The company has a PEG ratio of 1.83, compared to the industry average PEG ratio of 1.7 [8] Group 6: Industry Context - The Medical - Dental Supplies industry, part of the Medical sector, holds a Zacks Industry Rank of 26, placing it in the top 11% of over 250 industries [9]

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has McKesson (MCK) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.McKesson is one of 998 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual s ...

Company Overview - Henry Schein (HSIC) shares have increased by approximately 6.5% over the past month, outperforming the S&P 500 [1] - The most recent earnings report is crucial for understanding the catalysts affecting the stock [1] Earnings Estimates - Fresh estimates for Henry Schein have trended upward in the past month, indicating positive sentiment among analysts [2][4] - The stock has a Zacks Rank of 3 (Hold), suggesting an expectation of in-line returns in the upcoming months [4] VGM Scores - Henry Schein has a Growth Score of B and a Momentum Score of B, with an overall VGM Score of A, placing it in the top quintile for investment strategies [3] Industry Performance - Henry Schein is part of the Zacks Medical - Dental Supplies industry, where Becton Dickinson (BDX) has seen a 3.3% increase in the past month [5] - Becton Dickinson reported revenues of $5.27 billion for the last quarter, reflecting a year-over-year growth of 4.5% [5] - For the current quarter, Becton Dickinson is expected to report earnings of $3.45 per share, a decrease of 1.4% from the previous year [6]

Company Performance - McKesson (MCK) has returned approximately 26.6% since the beginning of the calendar year, outperforming the Medical sector, which has lost about 4.9% on average [4] - McKesson holds a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, with the consensus estimate for full-year earnings having increased by 1.4% over the past quarter [3] - McKesson belongs to the Medical - Dental Supplies industry, which includes 14 companies and currently ranks 84 in the Zacks Industry Rank, with this group having lost about 1.9% year-to-date [5] Industry Comparison - The Medical sector consists of 999 individual stocks and currently holds a Zacks Sector Rank of 4, which is based on the average Zacks Rank of the individual stocks within the sector [2] - Another stock in the Medical sector, Adagene Inc. Sponsored ADR (ADAG), has a year-to-date return of 4.8% and also holds a Zacks Rank of 2 (Buy), with its consensus EPS estimate increasing by 7.9% over the past three months [4][5] - The Medical - Biomedical and Genetics industry, which includes Adagene, has 503 stocks and is ranked 75, with this industry having moved -2.9% since the beginning of the year [6]

Core Viewpoint - The analysis compares Align Technology (ALGN) and Merit Medical (MMSI) to determine which stock is more attractive to value investors, highlighting ALGN's stronger earnings outlook and better valuation metrics [1][3]. Valuation Metrics - ALGN has a forward P/E ratio of 16.57, while MMSI has a forward P/E of 28.45, indicating that ALGN is potentially undervalued compared to MMSI [5]. - The PEG ratio for ALGN is 1.48, suggesting a favorable earnings growth outlook, whereas MMSI's PEG ratio is 2.77, indicating a less attractive growth relative to its price [5]. - ALGN's P/B ratio stands at 3.30, compared to MMSI's P/B of 3.95, further supporting ALGN's valuation advantage [6]. Earnings Outlook - ALGN is noted for its improving earnings outlook, which enhances its attractiveness in the Zacks Rank model, suggesting it is a superior value option compared to MMSI [7].